Citadel Advisors’s Medpace MEDP Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $2.4M | Sell |
5,000
-700
| -12% | -$358K | ﹤0.01% | 5707 |
|
|
2025
Q4 | $3.2M | Sell |
5,700
-4,600
| -45% | -$2.61M | ﹤0.01% | 5053 |
|
|
2025
Q3 | $5.3M | Buy |
10,300
+1,900
| +23% | +$830K | ﹤0.01% | 4260 |
|
|
2025
Q2 | $2.64M | Sell |
8,400
-4,700
| -36% | -$1.41M | ﹤0.01% | 5189 |
|
|
2025
Q1 | $3.99M | Sell |
13,100
-4,200
| -24% | -$1.41M | ﹤0.01% | 4260 |
|
|
2024
Q4 | $5.75M | Buy |
17,300
+1,700
| +11% | +$577K | ﹤0.01% | 3738 |
|
|
2024
Q3 | $5.21M | Buy |
15,600
+6,100
| +64% | +$2.32M | ﹤0.01% | 3874 |
|
|
2024
Q2 | $3.91M | Sell |
9,500
-28,800
| -75% | -$11.4M | ﹤0.01% | 4142 |
|
|
2024
Q1 | $15.5M | Buy |
38,300
+19,300
| +102% | +$6.79M | ﹤0.01% | 2362 |
|
|
2023
Q4 | $5.82M | Sell |
19,000
-5,100
| -21% | -$1.38M | ﹤0.01% | 3570 |
|
|
2023
Q3 | $5.84M | Sell |
24,100
-3,000
| -11% | -$767K | ﹤0.01% | 3414 |
|
|
2023
Q2 | $6.51M | Buy |
27,100
+12,200
| +82% | +$2.53M | ﹤0.01% | 3257 |
|
|
2023
Q1 | $2.8M | Buy |
14,900
+3,700
| +33% | +$765K | ﹤0.01% | 4756 |
|
|
2022
Q4 | $2.38M | Sell |
11,200
-35,700
| -76% | -$7.13M | ﹤0.01% | 5148 |
|
|
2022
Q3 | $7.37M | Buy |
46,900
+14,000
| +43% | +$2.23M | ﹤0.01% | 3221 |
|
|
2022
Q2 | $4.92M | Sell |
32,900
-21,200
| -39% | -$3.07M | ﹤0.01% | 3820 |
|
|
2022
Q1 | $8.85M | Buy |
54,100
+41,100
| +316% | +$6.78M | ﹤0.01% | 3150 |
|
|
2021
Q4 | $2.83M | Sell |
13,000
-10,100
| -44% | -$2.11M | ﹤0.01% | 5453 |
|
|
2021
Q3 | $4.37M | Sell |
23,100
-13,000
| -36% | -$2.37M | ﹤0.01% | 4569 |
|
|
2021
Q2 | $6.38M | Buy |
36,100
+18,500
| +105% | +$3.19M | ﹤0.01% | 3931 |
|
|
2021
Q1 | $2.89M | Buy |
17,600
+5,500
| +45% | +$841K | ﹤0.01% | 5538 |
|
|
2020
Q4 | $1.68M | Sell |
12,100
-500
| -4% | -$63K | ﹤0.01% | 5732 |
|
|
2020
Q3 | $1.41M | Buy |
12,600
+4,200
| +50% | +$486K | ﹤0.01% | 5389 |
|
|
2020
Q2 | $781K | Buy |
8,400
+900
| +12% | +$76.6K | ﹤0.01% | 6281 |
|
|
2020
Q1 | $550K | Buy |
7,500
+100
| +1% | +$8.68K | ﹤0.01% | 6315 |
|
|
2019
Q4 | $622K | Sell |
7,400
-10,400
| -58% | -$805K | ﹤0.01% | 6458 |
|
|
2019
Q3 | $1.5M | Buy |
17,800
+6,500
| +58% | +$491K | ﹤0.01% | 4936 |
|
|
2019
Q2 | $739K | Sell |
11,300
-11,100
| -50% | -$640K | ﹤0.01% | 6201 |
|
|
2019
Q1 | $1.32M | Buy |
22,400
+8,800
| +65% | +$526K | ﹤0.01% | 5115 |
|
|
2018
Q4 | $720K | Sell |
13,600
-8,700
| -39% | -$478K | ﹤0.01% | 5819 |
|
|
2018
Q3 | $1.34M | Buy |
+22,300
| New | +$1.22M | ﹤0.01% | 5058 |
|
Other funds holding MEDP
VPM
VCM
WA
Citadel Advisors's MEDP Position: Q1 2026 in Review
Citadel Advisors reduced its Medpace (MEDP) stake by 99% in Q1 2026, selling an estimated $30.2M and leaving 808 shares worth $388K. The position accounts for ﹤0.01% of the portfolio, ranked #9877.
Citadel Advisors first reported a position in MEDP in Q3 2016 and has held it in 34 quarters since. The position peaked at $37.7M in Q1 2024. 729 funds tracked by Wall St. Rank hold MEDP as of Q1 2026.
- Citadel Advisors held 808 shares of Medpace worth $388K as of Q1 2026.
- Citadel Advisors sold 58,932 Medpace shares in Q1 2026, an estimated $30.2M.
- Medpace made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #9877 holding.
- Citadel Advisors first reported a position in Medpace in Q3 2016 and has held it in 34 quarters since.
- Citadel Advisors's Medpace position peaked at $37.7M in Q1 2024.
- 729 funds tracked by Wall St. Rank held Medpace as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.